Europe
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
AstraZeneca signed a deal with Beijing-based Shenzhen Kangtai Biological Products to manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China.
Eliquis generic was approved by FDA to prevent strokes, blood clots etc. But there were some legal issues which recently got stave off. Know more about it here.
T-knife GmbH, based in Berlin, Germany, closed a €66 million (about $78.4 million, U.S.) Series A round.
Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
PRESS RELEASES